PHARMACEUTICAL COMPOSITIONS COMPRISING THE PPAR AGONIST INT-131 AND NRF2 ACTIVATORS
The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Europäisches Patentamt - (2019) vom: 19. Dez. Zur Gesamtaufnahme - year:2019 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
KAHRS BJOERN COLIN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2019-12-19, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-15 |
|---|
| Patentnummer: |
US2019381023 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000849871 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000849871 | ||
| 003 | DE-627 | ||
| 005 | 20240315102246.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000849871 | ||
| 035 | |a (EPA)US2019381023 | ||
| 035 | |a (EPA)48610741 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a KAHRS BJOERN COLIN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMPOSITIONS COMPRISING THE PPAR AGONIST INT-131 AND NRF2 ACTIVATORS |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2019-12-19, Last update posted on www.tib.eu: 2024-03-06, Last updated: 2024-03-15 | ||
| 520 | |a The invention relates to pharmaceutical compositions comprising PPAR agonists and Nrf2 activators and methods of using combinations of PPAR agonists and Nrf2 activators for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2019) vom: 19. Dez. |
| 773 | 1 | 8 | |g year:2019 |g day:19 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/48610741/publication/US2019381023A1?q=US2019381023 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2019 |b 19 |c 12 | ||